J Freireich loved good science and a good fight

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

When I started my fellowship at MD Anderson Cancer Center in 1980, Dr. Freireich headed the Department of Developmental Therapeutics.

In the departmental clinical research meetings, the fellows were sitting in the back and observed Dr. Freireich leading the meeting expecting accurate presentation and criticizing the most senior faculty, if needed.

People argued loudly in disagreement, only to be friendly to each other once the meeting was over. I learned soon that for J Freireich, scientific accuracy and knowledge were more important than seniority.

He never let any one of us get away with sloppy, inaccurate presentation.

Over the years I have learned about his multiple scientific accomplishments that significantly impacted the life of cancer patients. I was duly impressed. However, I was much more impressed with his personality as a leader.

He was a man of principles, and he never caved to pressure from administrators. He was always willing to give up political capital if it required compromising his scientific principles.

He was perceived by some as a controversial figure, at times upholding controversial concepts. Nonetheless, he defended his views rationally and with conviction.

Dr. Freireich was among those who pioneered clinical research in oncology as a structured, scientifically-supported discipline. He was among those who developed the therapeutic principles of chemotherapy in cancer.

At the same time, he also understood the changes in the fields and the value of therapeutic disciplines, such as biologic therapies, targeted therapies, and immunotherapies. Even in his later years, he was quick to grasp new concepts, remaining a sharp observer and critic when appropriate.

I see myself among many others who are Dr. Freireich’s proud students, who feel blessed to have had the opportunity to have him as a mentor who had considerable impact on their careers and lives.

The author is a professor at the Department of Internal Medicine,

University of Michigan

Moshe Talpaz
Professor, Department of Internal Medicine, University of Michigan
In This Issue


President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H.  “The discretionary request calls for $6.5 billion to...

Moshe Talpaz
Professor, Department of Internal Medicine, University of Michigan